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Usher syndrome type IIa is an autosomal recessive disorder characterized by mild-to-severe hearing loss and pro-
gressive visual loss due to retinitis pigmentosa. The mutation that most commonly causes Usher syndrome type
IIa is a 1-bp deletion, described as “2299delG,” in the USH2A gene. The mutation has been identified in several
patients from northern and southern Europe and from North America, and it has been found in single patients
from South America, South Africa, and China. Various studies have reported a range of frequencies (.16–.44) among
patients with Usher syndrome, depending on the geographic origin of the patients. The 2299delG mutation may
be the one that most frequently causes retinitis pigmentosa in humans. Given the high frequencies and the wide
geographic distribution of the mutation, it was of interest to determine whether the mutation resulted from an
ancestral mutational event or represented a mutational hotspot in the USH2A gene. Haplotype analysis was per-
formed on DNA samples from 116 unrelated patients with Usher syndrome type IIa; the patients were from 14
countries and represented 148 2299delG alleles. On the basis of six single-nucleotide polymorphisms within the
USH2A gene, 12 core haplotypes were observed in a panel of normal chromosomes. However, in our analysis,
only one core haplotype was found to be associated with the 2299delG mutation. The data indicate that the
widespread geographic distribution of the 2299delG mutation is the result of an ancestral mutation that has spread
throughout Europe and into the New World as a result of migration.
The Usher syndromes (MIM 276900) are a group of
recessively inherited disorders characterized by progres-
sive visual loss caused by retinitis pigmentosa (RP) and
by varying degrees of hearing impairment (which may
occur in the presence or absence of vestibular dysfunc-
tion) (Smith et al. 1994). The syndromes constitute the
most frequent cause of acquired deaf-blindness, with a
prevalence of 4.4:100,000 in the United States (Bough-
man et al. 1983) and 2.2:100,000 in Denmark (Rosen-
berg et al. 1997). Usher syndrome has been subcate-
gorized into three distinct clinical types and has been
linked to 10 distinct loci, USH1A–1F, USH2A–2C, and
USH3 (Hereditary Hearing Loss Home page). Usher
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type II probably accounts for more than half of all Usher
cases. Since the time of the initial identification of mu-
tations in the USH2A gene, which are responsible for
Usher syndrome type IIa and nonsyndromic retinitis pig-
mentosa (RP) (Eudy et al. 1998; Rivolta et al. 2000), a
total of 31 distinct disease-causing mutations have been
reported (Adato et al. 2000; Dreyer et al. 2000; Weston
et al. 2000). Most of the mutations are private. However,
the 2299delG mutation, in exon 13, stands out because
of its high frequency (.16–.44) across various studies
(Beneyto et al. 2000; Dreyer et al. 2000; Liu et al. 1999;
Weston et al. 2000). The mutation has been identified
in patients from northern and southern Europe and
North America and in single patients from South Amer-
ica, South Africa, and China.
Given the high frequencies of the 2299delG mutation
among patients with Usher type IIa and the mutation’s
wide geographic distribution, it was of interest to in-
vestigate whether the 2299delG alleles have a common
origin or represent a hotspot in the USH2A gene. We
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Figure 1 Relative locations of the SNPs and the 2299delG mutation within the USH2A gene and the three selected flanking markers.
Exons 1–21 are depicted as boxes and are numbered intermittently, for the sake of legibility. We used distance estimates that were derived from
Weston et al. (2000) and the Genome Database.
therefore analyzed DNA samples obtained from 116 un-
related patients with Usher type II, of whom 32 were
homoallelic and 84 were heteroallelic for the 2299delG
mutation. The patients originated in 14 countries: the
United States (43 patients), Denmark (22 patients), The
Netherlands (17 patients), United Kingdom (10 pa-
tients), Spain (6 patients), Sweden (6 patients), Norway
(4 patients), Belgium (2 patients), Canada (1 patient),
China (1 patient), Colombia (1 patient), France (1 pa-
tient), Germany (1 patient), and South Africa (1 patient);
all the United States patients were of European ancestry,
except for one African American.
To establish the haplotype for the 2299delG alleles,
six single-nucleotide polymorphisms (SNPs) within the
USH2A gene, exons 2–21, were selected (Dreyer et al.
2000). Two SNPs (IVS1535A/G and IVS178T/G)
were in noncoding sequence. Four SNPs were in cod-
ing sequence, of which two were synonymous (504G/A
and 1419C/T) and two were nonsynonymous (373A/G
and 4457A/G). In addition, three flanking markers,
AFM144XF2, AFM268ZD1, andAFM143XF10,which
span ∼460 kb of the USH2A locus, were included (fig.
1). The allele frequencies of these SNPs were established
in normal chromosomes from Norwegian nuclear fam-
ilies ( ), Spanish control chromosomes (np 108 np
), and in normal chromosomes from parents of pa-94
tients with Usher syndrome ( ). There were nonp 49
significant differences in allele frequencies among the
three control panels (data not shown).
SNP analysis was performed by PCR amplification in
a standard reaction mixture, as described by Dreyer et
al. (2000), except IVS1535A/G, which was detected
by allele-specific PCR using primers (reverse: 5′-GCAGT-
CCCCTGTATGATGATGC-3′; reverse: 5′-ATGCAGT-
CCCCTGTATGATGGTGT-3′; and forward: 5′-AAGC-
CGTCTTACTCTACAATGCT-3′). The products were
321 bp and 323 bp for IVS1535G and IVS1535A,
respectively. Fluorescence-labeled reverse primers were
used, and products were analyzed on a 377-ABI se-
quencer (Applied Biosystems). The underlined mis-
matches were introduced to increase the specific-
ity of the PCR. Genotyping for the three markers
(AFM144XF2, AFM268ZD1, and AFM143XF10) was
performed by use of information from the Genome Data-
base. The determination of haplotype phase was based
either on homozygosity or on the analysis of parental
samples, which could be used fully or partially to de-
termine the phase. A complete description of theUSH2A
haplotypes for the 148 USH2A alleles is presented in
table 1.
In all the 2299delG alleles for which the phase could
be determined (116 of 148), the 2299delG mutation was
associated with one core haplotype, A-G-C-A-T-A. In
the remaining 32 alleles, other haplotypes for the
2299delG allele would be formally possible; however,
the A-G-C-A-T-A core haplotype could not be excluded.
Except in one Spanish patient (SP4), the core haplotype
could be extended on the 3′ side, to span 325 kb (A-G-
C-A-T-A-250), including the marker AFM268ZD1.
Twelve different USH2A SNP haplotypes were ob-
served in a panel of normal chromosomes from Nor-
wegian nuclear families ( ); four major hap-np 108
lotypes (1–4) had frequencies of .60, .13, .06, and
.03, and eight derivative haplotypes showed frequen-
cies !.03. These haplotype frequencies were not sig-
nificantly different from those observed in chromo-
somes from parents of patients with Usher syndrome
( ) (table 2).np 49
Because of the wide geographic distribution of the
mutation and because of the haplotype heterogeneity at
the microsatellite markers (AFM144XF2,AFM268ZD1,
and AFM143XF10) that flank the USH2A locus, it had
been previously suggested that the 2299delG mutation
did not arise in a common ancestor (Eudy et al. 1998;
Liu et al. 1999). In our analysis, however, all 116
2299delG chromosomes for which the phase was known
were found to be in complete association with one spe-
cific core haplotype, which was designated “USH2A
haplotype 1.” Statistical significance of the association
was demonstrated using the x2 test ( ;2x p 57.2 P !
). The data strongly indicate that the 2299delG.001
alleles originated from an ancestral mutational event.
The variation at the flanking markers, especially the
AFM144XF2 and AFM143XF10, among the 2299delG
chromosomes probably reflects the generally high mu-
230
Table 1
Haplotypes Associated with the 2299delG Alleles in 116 Unrelated Patients of Geographically Diverse Origins
COUNTRY AND
PATIENT NUMBER
GENOTYPE AT
AFM144 XF2 373A/G 504G/A 1419C/T IVS1535A/G IVS178T/G 4457A/G AFM268ZD1 AFM143XF10
United States:
791a 116 A G C A T A 250 111
229 116 A G C A T A 250 111
126 A G C A T A 250 111
1143 126 A G C A T A 250 111
126 A G C A T A 250 111
2140 116 A G C A T A 250 111
116 A G C A T A 250 111
2720 126 A G C A T A 250 111
126 A G C A T A 250 111
52 116 A G C A T A 250 113
296 118/126 A G C A T A 250 111
427 116 A G C A T A 250 111
560 116/126 A G C A T A 250 111/115
685 126 A G C A T A 250 111
747 116 A G C A T A 250 111
777 116/126 A G C A T A 250 111/115
795 116 A G … A T A 250 111
869 116 A G C A T A 250 119
876 116/126 A G C A T A 250 109/111
225 126 A G C A T A 250 111/113
927 116 A G C A T A 250 119
1052 116/126 A G C A T A 250 107/111
1121 116/126 A G C A T A 250/254 111
1147 126 A G C A T A 250 111/113
1280 116/126 A G C A T A 250/254 111
1299 116/126 A G C A T A 250 111
1340 116/126 A G C A T … 250 111/113
1479 116 A G C A T A 250 111
2456 116/126 A G C A T A 250 111
2463 126 A G C A T A 250 …
2499 126 A G C A T A 250 115
2502 118 A G C A T A 250 111/113
2505 126 A G C A T A 250 115
2517 116/118 A G C A T A 250 …
2572 126 A G C A T A 250 107
2579 126 A G C A T A 250 111
2580 126 A G C A T A 250 111
2584 126 A G C A T A 250 113/115
2725 126 A G C A T A 250/252 113
2728 126 A G C A T A 250 111
1155 116/126 A G/A C A T A 250 111/115
2455 126 A G/A C A T A 250 111/113
1870 116/126 A G C A/G T A 250/252 107/111
2041 118 A G … A/G T A/G 250 …
2561 116/126 A G/A C/T A/G T/G A/G 250 111/113
2573 126 A G C/T A/G T/G A/G 250 111
2625 116 A/G G/A C A/G T A/G 250/256 111
Denmark:
D2 116 A G C A T A 250 113
116 A G C A T A 250 113
D4 116 A G C A T A 250 111
126 A G C A T A 250 111
D13 116 A G C A T A 250 113
116 A G C A T A 250 113
D18 126 A G C A T A 250 111
126 A G C A T A 250 113
(continued)
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Table 1 (continued)
COUNTRY AND
PATIENT NUMBER
GENOTYPE AT
AFM144 XF2 373A/G 504G/A 1419C/T IVS1535A/G IVS178T/G 4457A/G AFM268ZD1 AFM143XF10
D19 126 A G C A T A 250 111
126 A G C A T A 250 111
D40 116 A G C A T A 250 111/113
126 A G C A T A 250
D44 116 A G C A T A 250 111
116 A G C A T A 250 113
D5 126 A G C A T A 250 113
D7 126 A G C A T A 250 111
D8 116/126 A G C A T A 250 107/113
D10 126 A G C A T A 250 111/113
D15 116 A G C A T A 250 113
D16 116/126 A G C A T A 250 111
D22 116/126 A G C A T A 250 111
D24 116 A G C A T A 250 111/113
D39 116/118 A G C A T A 250 111/115
D32 116/126 A G C A/G T A/G … 111/115
D11 116/126 A/G G/A C/T A T A 250 111/115
D17 118/126 A G/A C/T A/G T A 250 107/111
D25 116 A G C/T A/G T A/G 250 109/113
D31 116 A G C A/G T/G A/G 250 113/115
D23 116/126 A G C/T A/G T/G A/G 250 111
The Netherlands:
1003 126 A G C A T A 250 115
126 A G C A T A 250 115
1011 126 A G C A T A 250 111
126 A G C A T A 250 111
1370 126 A G C A T A 250 111
126 A G C A T A 250 113
1374 126 A G C A T A 250 115
126 A G C A T A 250 115
1404 126 A G C A T A 250 113
126 A G C A T A 250 115
1298 126 A G C A T A 250 115
1375 126 A G C A T A 250 111
1386 128 A G C A T A 250 111
1387 126 A G C A T A 250 113
1415 126 A G C A T A 250 115
1044 116 A G C A T A 250 111
1238 126 A G C A T A 250 113
1420 118/126 A G C A T A 250 111
776 126 A G C A T A 250 107/113
1008 126 A G C A T A 250 111/115
1368 126 A G C A T A 250 111/113
956 126 A/G G/A C A T A/G 250 111
United Kingdom:b
UK1 126 A G C A T A 250 111
126 A G C A T A 250 111
UK2 116 A G C A T A 250 111
126 A G C A T A 250 111
UK5 116 A G C A T A 250 111
126 A G C A T A 250 111
UK7 116/126 A G C A T A 250 111/113
UK3 116/126 A G C A/G … A/G … 107/111
UK4 116/126 A G C A … A … 113
UK6 126 A/G G/A C A T A … 111
UK8 116/126 A/G G/A C/T A/G T/G A/G … 107/111
UK10 116/126 A G/A C A T A … 111/115
UK11c 116/126 A/G G/A … A/G … … … …
UK12 116/126 A G/A C A T A … …
(continued)
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Table 1 (continued)
COUNTRY AND
PATIENT NUMBER
GENOTYPE AT
AFM144 XF2 373A/G 504G/A 1419C/T IVS1535A/G IVS178T/G 4457A/G AFM268ZD1 AFM143XF10
Spain:
SP1 126 A G C A T A 250 113
126 A G C A T A 250 113
SP2 116 A G C A T A 250 111
116 A G C A T A 250 111
SP3 116 A G C A T A 250 111
116 A G C A T A 250 115
SP5 126 A G C A T A 250 111/115
1076 126 A G C A T A 250 111
SP4 116/118 A/G G/A C/T A/G T/G A/G 246/252 113
Sweden:
S1 116 A G C A T A 250 113
126 A G C A T A 250 113
S2 116 A G C A T A 250 111
126 A G C A T A 250 111
S3 116 A G C A T A 250 113
126 A G C A T A 250 113
S4 116 A G/A C A T A 250 111/115
S5 116 A/G G/A C/T A T A 250 111/113
S6 116/126 A/G G/A C/T A T A 250 113
Norway:
N4 116 A G C A T A 250 111
126 A G C A T A 250 111
N5 126 A G C A T A 250 111
126 A G C A T A 250 111
N25 116/126 A G C A T A 250 111/113
N15 116/126 A G C A/G T/G A/G 250 109/111
Belgium:
1862 116 A G C A T A 250 111
116 A G C A T A 250 111
1863 126 A G C A/G T/G A/G 250 115
Canada:
1158 128 A G/A C A T A 250 111
Colombia:
1150 116 A G C A T A 250 111
126 A G C A T A 250 111
France:
1223 116 A G C A T A 250 111
116 A G C A T A 250 113
Germany:
1294 116/118 A/G G/A C/T A/G T/G A/G 250 …
South Africa:
1128 126 A G C A T A 250 111
126 A G C A T A 250 111
NOTE.—Genotyping was incomplete in some patients because of a lack of DNA material.
a Patient was African American.
b Samples of genomic DNA of the patients in the United Kingdom were provided by Dr. Xue Zhong Liu.
c Patient was Chinese.
tation rate (103 to 104 per locus per generation) at
microsatellite sites (Weber and Wong 1993).
The fact that the 2299delG-associated haplotype is
also the most frequent in the unaffected population sug-
gests that the genetic distance between these two groups
is low. All but two of the patients in this study are Eu-
ropean or of European descent. It is tempting to spec-
ulate that the 2299delG mutation results from an old
mutational event that happened to arise on the most
common haplotype in the present European genetic
background and that was spread, through migration and
subsequent founder effects, throughout Europe. Fur-
thermore, the 2299delG mutation was probably brought
to the New World in recent times, because it occurs in
countries with a history of European immigration. This
definitely applies to the United States and to the singleton
patients in South Africa and Canada. However, two no-
table exceptions are the American patient of African an-
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Table 2
Frequencies of 2299delG and Normal Haplotypes
HAPLOTYPE
GENOTYPE ATa FREQUENCIES OF
373A/G
(.76/.24)
504G/A
(.72/.28)
1419C/T
(.78/.22)
IVS1535A/G
(.66/.34)
IVS178T/G
(.76/.24)
4457A/G
(.64/.36)
Normal
Control
Alleles
(n p 108)
Normal
Parental
Alleles
(n p 49)
2299delG
Alleles
(np 116)
1 A G C A T A .60 .53 1.00b
2 G A T G G G .13c .22c
3 A G C G G G .06 .02
4 G A C A T A .05 .04
5–12d … … … … … … .16 .19
a Genotypes are given according to SNPs (frequencies).
b Statistical significance of the association was measured by the x2 test ( x2 p 57.2, P ! .001).
c The frequency of haplotype 2 is higher than expected on the basis of the individual allele frequencies and illustrates a situation of
strong linkage disequilibrium, (x2 p 42.0, P ! .001).
d Eight haplotypes with frequencies !.03.
cestry (patient 791) and the patient of Chinese ancestry
(UK11, for whom the phase could not be determined).
Both patients are heterozygous for the 2299delG mu-
tation. A DNA sample from a Chinese patient who has
been reported to be homozygous for the 2299delG mu-
tation (Liu et al. 1999) was not available for this study.
Because no one has reported studies of 2299delG mu-
tation frequencies in non-European populations, it re-
mains to be elucidated whether 2299delG is present in
these two patients as a result of recent ethnic admixture
or is present in the gene pool of other populations such
as those of Africa and China.
In summary, our data provide the first molecular ev-
idence that the frequent and widespread 2299delG mu-
tation results from an ancient mutation of common or-
igin rather than from multiple recurrent mutational
events on a common haplotype. Although all the
2299delG alleles studied contain a conserved SNP core
haplotype that spans 1250 kb, the haplotype varies
widely, and the association between the 2299delG mu-
tation and the haplotypes of the flanking microsatellite
markers appears to be random. Regarding the physical
distances between these markers, this variability cannot
be explained by recombination alone (fig. 1). Thus, the
above data clearly demonstrate that, because of their
relatively high mutation frequency, microsatellites must
be applied in combination with SNP markers when
studying the origin and distribution of mutation.
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